We report a 52-year-old male with no family history of colonic cancer, who was found to have advanced colonic cancer with metastases two months post renal transplantation. With this case, we highlight the possibility of acute fulminant cancer metastases within short period after renal transplantation and the importance of periodic colorectal cancer screening pre-transplant. To our knowledge, this case is not yet reported in the literature, especially with such presentation of acute fulminant colonic cancer metastases post renal transplantation.

**Key words:** Adenocarcinoma of colon. Colon cancer. Renal transplantation. Immunosuppression. p53 gene mutation.

**CASE REPORT**

A 52-year-old male presented to our hospital with a one-day history of abdominal cramping pain, watery diarrhea and generalized fatigue. He had just undergone cadaveric renal transplantation two month ago. Abdominal sonography, taken one day post renal transplantation, revealed no remarkable findings. His renal graft function was stable on triple drug therapy including prednisolone, sirolimus, and mycophenolate mofetil (MMF). There is no bowel habit change or weight loss in recent two month after renal transplantation. On admission, his vital signs revealed temperature of 37.8 °C, pulse of 92/min and blood pressure of 116/68 mmHg. The blood tests showed white blood count of 4000/ul without predominant segmented neutrophils. Physical examination showed no remarkable findings except epigastric tenderness.

However, abdominal sonography revealed hypochoic lesions over liver and spleen two months later. Abdominal magnetic resonance image demonstrated lobulated heterogeneous mass about 4.5 x 5.5 x 3.6 cm at the segment 7 and a mild heterogeneous mass about 2.8 x 2.4 cm in the spleen (Fig. 1). Tumor marker studies showed CEA 7.09 ng/ml and CA199 3385 unit/ml. Sono-guided needle biopsy of the liver was performed and pathology showed metastatic adenocarcinoma of colon (Fig. 2). Colon fiberoscopy revealed one 1.4 cm ulcerative mass at splenic flexure, 60 cm from anal verge and biopsies of the lesion showed adenocarcinoma. Furthermore, immunostaining of paraffin-embedded sections revealed mutations of the p53 gene. Therefore, the patient was referred to oncological section for further chemotherapy with 5-fluorouracil and irinotecan.
DISCUSSION

In the current literature, colorectal cancer after renal transplantation is controversial and the reported time interval from transplant to colon cancer development ranged from 3.8 to 12.3 years (2). The American Society of Transplantation Clinical Practice Guide recommends the same standard colorectal cancer screening protocol for post-transplant recipients. There is no agreement as to whether colorectal cancer screening guidelines should be altered for post-replacement transplant patients, and most transplant registries seldom report whether aggressive or standard postoperative surveillance was administered.

Johnson et al. reported a median age of 58.7 years at the time of diagnosis and concluded that more than 25% of the at-risk population would have their tumors missed with adherence to current screening guidelines (3). They suggested that those older than age 50, a baseline pre-transplant screening colonoscopy should be obtained along with a follow-up surveillance exam 2 years after transplant. Although colorectal cancer may present earlier and act more aggressively in transplant recipients, more aggressive screening may continue in an at-risk population including two inherited conditions, familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer (4). Besides, p53 gene abnormality and immunosuppressive drugs may have accelerated the tumor onset and development (5).

With improvements in immunosuppressive regimens, malignancies have developed into a frequent long-term complication in kidney recipients. We reported this case of adenocarcinoma of colon with liver and spleen metastases approximately two months after kidney transplantation. While the developed colonic cancer with acute fulminant metastases may be associated with the likelihood of a pre-existing condition which could not be early detected, this aggressive course is believed to be associated with the use of immunosuppressive drugs and p53 gene abnormality. We suggested that more aggressive screening for malignancy studies before renal transplantation, though the age and the timing to initiate screening remain to be determined.

REFERENCES